Chhanda was born and grew up in the state of Odisha, India. He worked on design and synthesis of potential quinazoline derivatives as anticancer and anticonvulsant agents with Dr Senthil Raja A. at Banaras Hindu University, India. He did his PhD from Panjab University, India with Prof. Poonam Piplani and worked on design, synthesis and evaluation of potential piperazine derivatives as cognition enhancers. He designed compounds through molecular docking and Pharmacophore based and screened them via in vitro acetylcholinesterase inhibition and enzyme kinetics, and in vivo passive avoidance using mice, and ex vivo models. He then backed to Banaras Hindu University to join Prof. Sushant Kumar Shrivastava research group and synthesized some heterocyclic compounds for the treatment of neurodegenerative diseases. He awarded Royal Society-SERB Newton International Fellowship from The Royal Society, London, and moved to join Dr Klaus Pors at University of Bradford, UK and worked on synthesis of hypoxia activated fluorescent probes, aldehyde dehydrogenase (ALDH) inhibitors and DNA-intercalating alkylating agents for the detection and treatment of cancer. He joined with Dr Sam Xu at University of Hull and worked on synthesis of potential H2S releasing compounds and investigated for the treatment of diabetic kidney disease (DKD) through oxidative stress and cellular calcium signaling. He has also industrial experience working on robust organic synthesis and prediction of retrosynthetic routes for natural products. He is very passionate on new drug discovery and always worried for the discovery of new potential safe therapeutics for the wellbeing of human beings. Away from chemistry and pharmacology, he loves playing football and cricket, walking and cycling, reading and thinking, and enjoying nature.